These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 8682282)

  • 1. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
    Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
    Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
    MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
    Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers].
    Göhring UJ; Scharl A; Thelen U; Ahr A; Titius BR
    Pathologe; 1995 Nov; 16(6):398-403. PubMed ID: 8570558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
    Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
    J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
    Abadjian G; Antoun R
    J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors in breast cancer patients].
    Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
    Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
    Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
    Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.